Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANFIRE-III: IRE + Nivolumab +/- Tilsotolimod in Oligometastatic Pancreatic Cancer
NCT04612530Phase 1Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2020
- Primary completion
- Apr 2023
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nivolumab and tilsotolimod in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Safety of the combination treatment IRE + immunotherapy based on adverse events at 1 year. Status: unknown.
02
Drugs
nivolumabtilsotolimod
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04612530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612530.